Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Analysing propensity score methods on two randomized controlled clinical trials

Autor: Dieckmann, D, Götte, H, Jahn, A

Publikováno v: 65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS); 20200906-20200909; Berlin; DOCAbstr. 372 /20210226/

Background: Propensity score methods has been widely used in observational studies and growingly seen as a solution for evaluating treatment effects in non-randomized controlled trials using external controls. They account only for observable confoun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9112b2b6370025e562cbb77bc8b4f14a

An adaptive design for early drug development including interim decision for single-arm trial with external controls or randomized trial

Autor: Götte, H, Kirchner, M, Krisam, J, Allignol, A, Lamy, FX, Schüler, A, Kieser, M

Publikováno v: 65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS); 20200906-20200909; Berlin; DOCAbstr. 226 /20210226/

Background: In early clinical development, where only few drug candidates have the potential for market approval, the gold standard, a randomized controlled trial (RCT) might not be the most efficient option for ethical and economic reasons. The requ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985aa00f63633b8f8e7e26ccee939ef3

Optimal designs for phase II/III drug development programs facilitated by R Shiny applications

Autor: Preussler, S, Kirchner, M, Götte, H, Kieser, M

Publikováno v: 64. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS); 20190908-20190911; Dortmund; DOCAbstr. 168 /20190906/

Introduction: Recently, a utility-based approach was proposed to optimize planning of phase II/III drug development programs in terms of sample size allocation and go/no-go decision rules (whether to stop or to proceed to phase III) [ref:1]. The util

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1516fbbcfeac6bef2bd7981817d5f488

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Autor: Lordick, F., Kang, Y. K., Chung, H. C., Salman, P., Oh, S. C., Bodoky, G., Kurteva, G., Volovat, C., Moiseyenko, V. M., Gorbunova, V., Park, J. O., Sawaki, A., Celik, I., Götte, H., Melezínková, H., Moehler, M., Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators

Publikováno v: The Lancet Oncology. 14:490-499

Summary Background Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine-cisplatin chemotherapy in patients with advanced gastric or gastro-oeso

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4e650eb0c6563e905b503487ccae467
https://doi.org/10.1016/s1470-2045(13)70102-5